var data={"title":"Fentanyl: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fentanyl: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6188?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fentanyl-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fentanyl: Patient drug information&quot;</a> and <a href=\"topic.htm?path=fentanyl-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fentanyl: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50847583\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708780\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression has occurred with use of fentanyl, including following use in opioid non-tolerant patients and improper dosing. Monitor for respiratory depression, especially during initiation of fentanyl or following a dose increase. The substitution of fentanyl buccal, intranasal, lozenge, or sublingual for any other fentanyl product may result in fatal overdose. Due to the risk of respiratory depression, fentanyl buccal, intranasal, lozenge, and sublingual are contraindicated in the management of acute or postoperative pain including headache/migraine and in opioid non-tolerant patients; fentanyl transdermal is contraindicated for use as an as-needed analgesic, in nonopioid tolerant patients, in acute pain, and in postoperative pain. Only the patient should activate Ionsys dosing.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fentanyl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing fentanyl, and monitor all patients regularly for the development of these behaviors and conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental exposure:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Accidental exposure of even one dose of fentanyl, especially by children, can result in a fatal overdose of fentanyl. Death has been reported in children who have accidentally ingested transmucosal immediate-release fentanyl products. Deaths due to a fatal overdose of fentanyl have occurred when children and adults were accidentally exposed to fentanyl transdermal patch. Strict adherence to the recommended handling and disposal instructions is of the utmost importance to prevent accidental exposure. Fentanyl must be kept out of reach of children.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cytochrome P450 3A4 Interaction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concomitant use of fentanyl with all cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in fentanyl plasma concentration. Monitor patients receiving fentanyl and any CYP3A4 inhibitor or inducer.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal opioid withdrawal syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of fentanyl during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of fentanyl and benzodiazepine or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of medication errors (buccal, intranasal, lozenge, sublingual):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Substantial differences exist in the pharmacokinetic profile of fentanyl buccal, intranasal, lozenge, and sublingual compared with other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl that could result in fatal overdose. When prescribing, do not convert patients on a mcg-per-mcg basis from any other fentanyl products to fentanyl buccal, intranasal, lozenge, or sublingual. When dispensing, do not substitute a fentanyl buccal, intranasal, lozenge, or sublingual prescription for other fentanyl products.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">REMS program:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Buccal, intranasal, lozenge, sublingual: Because of the risk for misuse, abuse, addiction, and overdose, fentanyl buccal, intranasal, lozenge, and sublingual are available only through a restricted program required by the FDA, called a Risk Evaluation and Mitigation Strategy (REMS). Under the Transmucosal Immediate Release Fentanyl (TIRF) REMS Access Program, outpatients, health care providers who prescribe to outpatients, pharmacies, and distributors must enroll in the program. Further information is available at http://www.TIRFREMSaccess.com or by calling 1-866-822-1483.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal iontophoretic system (Ionsys): For use only in patients in the hospital. Discontinue treatment with before patients leave the hospital. Because of the risk of respiratory depression from accidental exposure, Ionsys is available through a restricted program called the Ionsys REMS Program. Healthcare facilities that dispense Ionsys must be certified in this program and comply with the REMS requirements.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exposure to heat (Duragesic only):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Exposure of the fentanyl application site and surrounding area to direct external heat sources, such as heating pads or electric blankets, heat or tanning lamps, sunbathing, hot baths, saunas, hot tubs, and heated water beds may increase fentanyl absorption and has resulted in fatal overdose of fentanyl. Warn patients to avoid exposing the application site and surrounding area to direct external heat sources.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170610\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Abstral;</li>\n      <li>Actiq;</li>\n      <li>Duragesic;</li>\n      <li>Fentora;</li>\n      <li>Ionsys;</li>\n      <li>Lazanda;</li>\n      <li>Onsolis [DSC];</li>\n      <li>Sublimaze;</li>\n      <li>Subsys</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170611\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Abstral;</li>\n      <li>Duragesic;</li>\n      <li>Fentora</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170659\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Opioid;</li>\n      <li>\n        Anilidopiperidine Opioid;</li>\n      <li>\n        General Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170615\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Ranges listed may not represent the maximum doses that may be required in some patients. Doses and dosage intervals should be titrated to pain relief/prevention. Monitor vital signs routinely. Single IM doses have duration of 1-2 hours, single IV doses last 0.5 to 1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgery:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premedication: IM, slow IV: 50 to 100 mcg administered 30 to 60 minutes prior to surgery <b>or</b> slow IV: 25 to 50 mcg given shortly before induction (Barash 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjunct to general anesthesia: Slow IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low dose: 1 to 2 mcg/<b>kg</b> depending on the indication (Miller 2010); additional maintenance doses are generally not needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate dose (fentanyl plus a sedative/hypnotic): Initial: 2 to 4 mcg/<b>kg</b>; Maintenance (bolus or infusion): 25 to 50 mcg every 15 to 30 minutes or 0.5 to 2 mcg/kg/<b>hour</b> (Miller 2010). Discontinuing fentanyl infusion 30 to 60 minutes prior to the end of surgery will usually allow adequate ventilation upon emergence from anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High dose (opioid anesthesia): 4 to 20 mcg/<b>kg</b> bolus then 2 to 10 mcg/kg/<b>hour</b> (Miller 2010); <b>Note:</b> High-dose fentanyl (ie, 20 to 50 mcg/kg) is rarely used, but is still described in the manufacturer&rsquo;s label. The concept of fast-tracking and early extubation following cardiac surgery has essentially replaced high-dose fentanyl anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjunct to regional anesthesia: 50 to 100 mcg IM or slow IV over 1 to 2 minutes. <b>Note:</b> An IV should be in place with regional anesthesia so the IM route is rarely used but still maintained as an option in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postoperative recovery: IM: 50 to 100 mcg every 1 to 2 hours as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postoperative pain: Epidural (Canadian labeling; not in US labeling): Initial: 100 mcg (diluted in 8 mL of preservative free NS to final concentration of 10 mcg/mL); may repeat with additional 100 mcg boluses on demand or alternatively may administer by continuous infusion at a rate of 1 mcg/kg/hour.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative pain, acute:</b> Transdermal device (Ionsys): Apply one device to chest or upper outer arm only. Only the patient may activate the device (40 mcg dose of fentanyl per activation; maximum 6 doses per hour). Only one device may be applied at a time for up to 24 hours or 80 doses, whichever comes first. May be used for a maximum of 72 hours, with each subsequent device applied to a different skin site. If inadequate analgesia is achieved with one device, either provide additional supplemental analgesic medication or replace with an alternate analgesic medication. Refer to manufacturer&rsquo;s labeling for activation instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> For hospital use only by patients under medical supervision and direction and only after patients have been titrated to an acceptable level of analgesia using another opioid analgesic.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe pain:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intermittent dosing:</i> IM, IV (off-label dose): Slow IV: 25 to 35 mcg (based on ~70 kg patient) <b>or</b> 0.35 to 0.5 mcg/kg every 30 to 60 minutes as needed (SCCM [Barr, 2013]). <b>Note:</b> After the first dose, if severe pain persists and adverse effects are minimal at the time of expected peak effect (eg, ~5 minutes after IV administration), may repeat dose (APS, 2008). In addition, since the duration of activity with IV administration is 30 to 60 minutes, more frequent administration may be necessary when administered by this route.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patient-controlled analgesia (PCA) (off-label use; American Pain Society, 2008; Miller, 2010): Opioid-naive:</i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual concentration: 10 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Demand dose: Usual: 10 to 20 mcg</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">Lockout interval: 4 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual basal rate: &le;50 mcg/hour. <b>Note:</b> Continuous basal infusions are not recommended for initial programming and should rarely be used; consider limiting infusion rate to 10 mcg/hour if used (Grass, 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Critically-ill patients (off-label dose):</i> Slow IV: 25 to 35 mcg (based on ~70 kg patient) <b>or</b> 0.35 to 0.5 mcg/kg every 30 to 60 minutes as needed (SCCM [Barr, 2013]). <b>Note:</b> More frequent dosing may be needed (eg, mechanically-ventilated patients).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous infusion: 50 to 700 mcg/hour (based on ~70 kg patient) <b>or</b> 0.7 to 10 mcg/kg/<b>hour </b> (SCCM [Barr, 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternative continuous infusion dosing: 1 to 2 mcg/kg bolus followed by an initial rate of 1 to 2 mcg/<b>kg</b>/hour (Peng, 1999) <b>or</b> 25 to 100 mcg bolus followed by an initial rate of 25 to 200 mcg/<b>hour</b> (Liu, 2003). <b>Note:</b> When pain is not controlled, may administer an additional small bolus dose (eg, 25 to 50 mcg) prior to increasing the infusion rate (Loper 1990; Peng, 1999; Salomaki, 1991).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intrathecal (off-label use; American Pain Society, 2008): <b>Must be preservative-free.</b> Doses must be adjusted for age, injection site, and patient&rsquo;s medical condition and degree of opioid tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Single dose: 5 to 25 mcg; may provide adequate relief for up to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous infusion: Not recommended in acute pain management due to risk of excessive accumulation. For chronic cancer pain, infusion of very small doses may be practical (American Pain Society, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Epidural (off-label use; American Pain Society, 2008): <b>Must be preservative-free.</b> Doses must be adjusted for age, injection site, and patient&rsquo;s medical condition and degree of opioid tolerance</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Single dose: 25 to 100 mcg; may provide adequate relief for up to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous infusion: 25 to 100 mcg/hour (fentanyl alone). When combined with a local anesthetic (eg, bupivacaine or ropivacaine), fentanyl requirement are less (Manion, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breakthrough cancer pain: </b> Transmucosal: For patients who are tolerant to and currently receiving opioid therapy for persistent cancer pain; dosing should be individually titrated to provide adequate analgesia with minimal side effects. Dose titration should be done if patient requires more than 1 dose/breakthrough pain episode for several consecutive episodes. Patients experiencing &gt;4 breakthrough pain episodes per day should have the dose of their long-term opioid re-evaluated. <b>Patients must remain on around-the-clock opioids during use.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lozenge (Actiq): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Actiq on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 200 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 200 mcg (consumed over 15 minutes) for all patients; if after 30 minutes from the start of the lozenge (ie, 15 minutes following the completion of the lozenge), the pain is unrelieved, a second 200 mcg dose may be given over 15 minutes. A maximum of 1 additional dose can be given per pain episode; <b>must wait at least 4 hours before treating another episode</b>. To limit the number of units in the home during titration, only prescribe an initial titration supply of six 200 mcg lozenges.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration: From the initial dose, closely follow patients and modify the dose until patient reaches a dose providing adequate analgesia using a single dosage unit per breakthrough cancer pain episode. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient&rsquo;s mouth, dispose of properly, and reduce subsequent doses. If adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given for that episode; <b>must wait at least 4 hours before treating another episode.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Once titrated to an effective dose, patients should generally use a single dosage unit per breakthrough pain episode. During any pain episode, if adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given over 15 minutes for that episode; <b>must wait at least 4 hours before treating another episode</b>. Consumption should be limited to &le;4 units per day (once an effective breakthrough dose is found). If adequate analgesia is <b>not </b>provided after treating several episodes of breakthrough pain using the same dose, increase dose to next highest lozenge strength (initially dispense no more than 6 units of the new strength). Re-evaluate the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient&rsquo;s mouth, dispose of properly, and reduce subsequent doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal film (Onsolis): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Onsolis on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 200 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 200 mcg for all patients; if after 30 minutes pain is unrelieved, the patient may use an alternative rescue medication as directed by their health care provider. Do <b>not</b> redose with Onsolis within an episode; buccal film should only be used once per breakthrough cancer pain episode. <b>Must wait at least 2 hours before treating another episode with buccal film.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration: If titration required, increase dose in 200 mcg increments once per episode using multiples of the 200 mcg film (for doses up to 800 mcg); do not redose within a single episode of breakthrough pain and separate single doses by &ge;2 hours. During titration, do not exceed 4 simultaneous applications of the 200 mcg films (800 mcg) (when using multiple films, do not place on top of each other; film may be placed on both sides of mouth); if &gt;800 mcg required, treat next episode with one 1,200 mcg film (maximum dose: 1,200 mcg). Once maintenance dose is determined, all other unused films should be disposed of and that strength (using a single film) should be used. During any pain episode, if adequate relief is not achieved after 30 minutes following buccal film application, a rescue medication (as determined by health care provider) may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Determined dose applied as a single film once per episode and separated by &ge;2 hours (dose range: 200 to 1,200 mcg); limit to 4 applications per day. Consider increasing the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal tablet (Fentora): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Fentora on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects. For patients previously using the transmucosal lozenge (Actiq), the initial dose should be selected using the conversions listed; see <i>Conversion from lozenge (Actiq) to buccal tablet (Fentora)</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 100 mcg for all patients unless patient already using Actiq; see <i>Conversion from lozenge (Actiq) to buccal tablet (Fentora)</i>; if after 30 minutes pain is unrelieved, the US labeling suggests that a second 100 mcg dose may be administered (maximum of 2 doses per breakthrough pain episode). The Canadian labeling recommends only a single dose per breakthrough pain episode; patients experiencing breakthrough pain after administration may take an alternative analgesic as rescue medication after 30 minutes. <b>Must wait at least 4 hours before treating another episode with Fentora buccal tablet.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration: If titration required, 100 mcg dose may be increased to 200 mcg using two 100 mcg tablets (one on each side of mouth) with the next breakthrough pain episode. If 200 mcg dose is not successful, patient can use four 100 mcg tablets (two on each side of mouth) with the next breakthrough pain episode. If titration requires &gt;400 mcg per dose, titrate using 200 mcg tablets; do not use more than 4 tablets simultaneously (maximum single dose: 800 mcg). During any pain episode, if adequate relief is not achieved after 30 minutes following buccal tablet application, a second dose of same strength per breakthrough pain episode may be used. The Canadian labeling recommends only a single dose per breakthrough pain episode; patients experiencing breakthrough pain after administration may take an alternative analgesic as rescue medication after 30 minutes. <b>Must wait at least 4 hours before treating another episode with Fentora buccal tablet. </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Following titration, the effective maintenance dose using 1 tablet of the appropriate strength should be administered once per episode; if after 30 minutes pain is unrelieved, may administer a second dose of the same strength; The Canadian labeling recommends only a single dose per breakthrough pain episode; patients experiencing breakthrough pain after administration may take an alternative analgesic as rescue medication after 30 minutes. <b>Must wait &ge;4 hours before treating another episode with Fentora buccal tablet.</b> Limit to 4 applications per day. Re-evaluate the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day. Once an effective maintenance dose has been established, the buccal tablet may be administered sublingually (alternate route). To prevent confusion, patient should only have one strength available at a time. Once maintenance dose is determined, all other unused tablets should be disposed of and that strength (using a single tablet) should be used. Using more than four buccal tablets at a time has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion from lozenge (Actiq) to buccal tablet</i> (Fentora):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lozenge dose 200 to 400 mcg: Initial buccal tablet dose is 100 mcg; may titrate using multiples of 100 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lozenge dose 600 to 800 mcg: Initial buccal tablet dose is 200 mcg; may titrate using multiples of 200 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lozenge dose 1,200 to 1,600 mcg: Initial buccal tablet dose is 400 mcg (using two 200 mcg tablets); may titrate using multiples of 200 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal (Lazanda): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Lazanda on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 100 mcg (one 100 mcg spray in one nostril) for all patients; if after 30 minutes pain is unrelieved, an alternative rescue medication may be used as directed by their health care provider. <b>Must wait at least 2 hours before treating another episode with fentanyl intranasal.</b> However, for the next pain episode, increase to a higher dose using the recommended dose titration steps.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration: If titration required, increase to a higher dose for the next pain episode using these titration steps <b>(Note: Must wait at least 2 hours before treating another episode with fentanyl intranasal)</b>: If no relief with 100 mcg dose, increase to 200 mcg dose per episode (one 100 mcg spray in each nostril); if no relief with 200 mcg dose, increase to 300 mcg dose per episode (alternating one 100 mcg spray in right nostril, one 100 mcg spray in left nostril, and one 100 mcg spray in the right nostril); if no relief with 300 mcg dose, increase to 400 mcg per episode (one 400 mcg spray in one nostril or alternating two 100 mcg sprays in each nostril); if no relief with 400 mcg dose, increase to 600 mcg dose per episode (one 300 mcg spray in each nostril); if no relief with 600 mcg dose, increase to 800 mcg dose per episode (one 400 mcg spray in each nostril). <b>Note:</b> Single doses &gt;800 mcg have not been evaluated. There are no data supporting the use of a combination of dose strengths. Avoid use of a combination of dose strengths to treat an episode, as this may cause confusion and dosing errors.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. For pain that is not relieved after 30 minutes of Lazanda administration or if a separate breakthrough pain episode occurs within the 2 hour window before the next Lazanda dose is permitted, a rescue medication may be used. Limit Lazanda use to &le;4 episodes of breakthrough pain per day. If patient is experiencing &gt;4 breakthrough pain episodes per day, consider increasing the around-the-clock, long-acting opioid therapy; if long-acting opioid therapy dose is altered, re-evaluate and retitrate Lazanda dose as needed. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual spray (Subsys): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Subsys on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects. For patients previously using the transmucosal lozenge (Actiq), the initial dose should be selected using the conversions listed; see <i>Conversion from lozenge (Actiq) to sublingual spray (Subsys)</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 100 mcg for all patients unless patient already using Actiq; see <i>Conversion from lozenge (Actiq) to sublingual spray (Subsys)</i>. If pain is unrelieved, 1 additional 100 mcg dose may be given 30 minutes after administration of the first dose. A maximum of 2 doses can be given per breakthrough pain episode. <b>Must wait at least 4 hours before treating another episode with sublingual spray.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration: If titration required, titrate to a dose that provides adequate analgesia (with tolerable side effects) using the following titration steps: If no relief with 100 mcg dose, increase to 200 mcg dose (using one 200 mcg unit); if no relief with 200 mcg dose, increase to 400 mcg dose (using one 400 mcg unit); if no relief with 400 mcg dose, increase to 600 mcg dose (using one 600 mcg unit); if no relief with 600 mcg dose, increase to 800 mcg dose (using one 800 mcg unit); if no relief with 800 mcg dose, increase to 1200 mcg dose (using two 600 mcg units); if no relief with 1200 mcg dose, increase to 1600 mcg dose (using two 800 mcg units). During dose titration, if breakthrough pain unrelieved 30 minutes after Subsys administration, 1 additional dose using the same strength may be administered (maximum: 2 doses per breakthrough pain episode); <b>patient must wait 4 hours before treating another breakthrough pain episode with sublingual spray.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. If occasional episodes of unrelieved breakthrough pain occur following 30 minutes of Subsys administration, 1 additional dose using the same strength may be administered (maximum: 2 doses per breakthrough pain episode); <b>patient must wait 4 hours before treating another breakthrough pain episode with Subsys.</b> Once maintenance dose is determined, limit Subsys use to &le;4 episodes of breakthrough pain per day. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary. If patient is experiencing &gt;4 breakthrough pain episodes per day, re-evaluate the around-the-clock, long-acting opioid therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion from lozenge (Actiq) to sublingual spray (Subsys):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lozenge dose 200 to 400 mcg: Initial sublingual spray dose is 100 mcg; may titrate using multiples of 100 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lozenge dose 600 to 800 mcg: Initial sublingual spray dose is 200 mcg; may titrate using multiples of 200 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lozenge dose 1,200 to 1,600 mcg: Initial sublingual spray dose is 400 mcg; may titrate using multiples of 400 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet (Abstral): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Abstral on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg (except Actiq); individually titrate to provide adequate analgesia while minimizing adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>US labeling:</i> 100 mcg for all patients; if pain is unrelieved, a second 100 mcg dose may be given 30 minutes after administration of the first dose. A maximum of 2 doses can be given per breakthrough pain episode. <b>Must wait at least 2 hours before treating another episode with sublingual tablet.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Canadian labeling:</i> 100 mcg for all patients; if pain is unrelieved 30 minutes after administration of Abstral, an alternative rescue medication (other than Abstral) may be given. Administer only 1 dose of Abstral per breakthrough pain episode. <b>Must wait at least 2 hours before treating another episode with sublingual tablet.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration: If titration required, increase in 100 mcg increments (up to 400 mcg) over consecutive breakthrough episodes. If titration requires &gt;400 mcg per dose, increase in increments of 200 mcg, starting with 600 mcg dose and titrating up to 800 mcg. During titration, patients may use multiples of 100 mcg and/or 200 mcg tablets for any single dose; do not exceed 4 tablets at one time; safety and efficacy of doses &gt;800 mcg have not been evaluated. During dose titration, if breakthrough pain unrelieved 30 minutes after sublingual tablet administration, the US labeling suggests that 1 additional dose using the same strength may be administered (maximum: 2 doses per breakthrough pain episode); the Canadian labeling recommends use of an alternative rescue medication and limits use of Abstral to 1 dose per breakthrough pain episode. <b>Patient must wait 2 hours before treating another breakthrough pain episode with sublingual tablet.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Once maintenance dose for breakthrough pain episode has been determined, use only 1 tablet in the appropriate strength per episode; if pain is unrelieved with maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>US labeling:</i> A second dose may be given after 30 minutes; maximum of 2 doses/episode of breakthrough pain; separate treatment of subsequent episodes by &ge;2 hours; limit treatment to &le;4 breakthrough episodes per day.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Canadian labeling:</i> Administer alternative rescue medication after 30 minutes; maximum of 1 Abstral dose/episode of breakthrough pain; separate treatment of subsequent episodes by &ge;2 hours; limit treatment to &le;4 breakthrough episodes per day.</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Consider re-evaluating the around-the-clock long-acting opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day; if long-acting opioid therapy dose altered, re-evaluate and retitrate Abstral dose as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion from lozenge (Actiq) to sublingual tablet (Abstral):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lozenge dose 200 mcg: Initial sublingual tablet dose is 100 mcg; may titrate using multiples of 100 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lozenge dose 400 to 1,200 mcg: Initial sublingual tablet dose is 200 mcg; may titrate using multiples of 200 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lozenge dose 1,600 mcg: Initial sublingual tablet dose is 400 mcg; may titrate using multiples of 400 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinuation of therapy: Gradually titrate dose downward to prevent withdrawal signs/symptoms. In patients who continue to take chronic opioid therapy for persistent pain but no longer require treatment for breakthrough pain, fentanyl for breakthrough pain can usually be discontinued immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Chronic pain management (opioid-tolerant patients only):</b> Transdermal patch: Discontinue or taper all other around-the-clock or extended release opioids when initiating therapy with fentanyl transdermal patch.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: To convert patients from oral or parenteral opioids to fentanyl transdermal patch, a 24-hour analgesic requirement should be calculated (based on prior opioid use). Using the tables below, the appropriate initial dose can be determined. The initial fentanyl dosage may be approximated from the 24-hour morphine dosage equivalent and titrated to minimize adverse effects and provide analgesia. Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient&rsquo;s daily fentanyl requirement and provide breakthrough pain relief with rescue medication (eg, immediate release opioid) than to overestimate requirements. With the initial application, the absorption of transdermal fentanyl requires several hours to reach plateau; therefore transdermal fentanyl is inappropriate for management of acute pain. Change patch every 72 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from continuous infusion of fentanyl: In patients who have adequate pain relief with a fentanyl infusion, fentanyl may be converted to transdermal dosing at a rate equivalent to the intravenous rate. A two-step taper of the infusion to be completed over 12 hours has been recommended (Kornick, 2001) after the patch is applied. The infusion is decreased to 50% of the original rate six hours after the application of the first patch, and subsequently discontinued twelve hours after application.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Titration: Short-acting agents may be required until analgesic efficacy is established and/or as supplements for &ldquo;breakthrough&rdquo; pain. The amount of supplemental doses should be closely monitored. Appropriate dosage increases may be based on daily supplemental dosage using the ratio of 45 mg/24 hours of oral morphine to a 12 mcg/hour increase in fentanyl dosage (US labeling) or using the ratio of 45 to 59 mg/24 hours of oral morphine to a 12 mcg/hour increase in fentanyl dosage (Canadian labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Frequency of adjustment: </i>The dosage should not be titrated more frequently than every 3 days after the initial dose or every 6 days thereafter. Titrate dose based on the daily dose of supplemental opioids required by the patient on the second or third day of the initial application. <b>Note:</b> Upon discontinuation, &ge;17 hours are required for a 50% decrease in fentanyl levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Frequency of application: </i>The majority of patients may be controlled on every 72-hour administration; however, a small number of adults require every 48-hour administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Discontinuation of therapy:</b> When discontinuing transdermal fentanyl and not converting to another opioid, use a gradual downward titration, such as decreasing the dose by 50% every 6 days. If patient displays withdrawal symptoms, increase dose to previous level and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dose conversion guidelines for transdermal fentanyl (see tables).</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> US and Canadian dose conversion guidelines differ; consult appropriate table. The conversion factors in these tables are only to be used for the conversion from current opioid therapy to Duragesic. Conversion factors in this table cannot be used to convert from Duragesic to another opioid (doing so may lead to fatal overdose due to overestimation of the new opioid). These are not tables of equianalgesic doses.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">U.S. Labeling: Dose Conversion Guidelines: Recommended Initial Duragesic Dose Based Upon Daily Oral Morphine Dose<sup>1,2</sup></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Oral 24-Hour Morphine</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duragesic Dose<sup>3,4</sup></p>\n            <p style=\"text-indent:0em;\">(mcg/h)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>1</sup>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>2</sup>Recommendations are based on U.S. product labeling for Duragesic.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>3</sup>Pediatric patients initiating therapy on a 25 mcg/hour Duragesic system should be opioid-tolerant and receiving at least 60 mg oral morphine equivalents per day.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>4</sup>A fentanyl 37.5 mcg/hour transdermal system is also available and may be considered during conversion from prior opioids or dose titration.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 134</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">135 to 224</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">225 to 314</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">315 to 404</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">405 to 494</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">495 to 584</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">585 to 674</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">175</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">675 to 764</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">765 to 854</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">225</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">855 to 944</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">945 to 1,034</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">275</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,035 to 1,124</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">U.S. Labeling: Dose Conversion Guidelines<sup>1,2</sup></caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Current Analgesic</p></th>\n          <th colspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Daily Dosage</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>Recommendations are based on U.S. product labeling for Duragesic.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Morphine (IM/IV)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 22</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">23 to 37</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">38 to 52</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">53 to 67</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Oxycodone (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 67</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">67.5 to 112</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">112.5 to 157</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">157.5 to 202</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Codeine (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 to 447</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">-</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">-</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">-</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Hydromorphone (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 17</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">17.1 to 28</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">28.1 to 39</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">39.1 to 51</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Hydromorphone (IV)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.5 to 3.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.5 to 5.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.7 to 7.9</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 10</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Meperidine (IM)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75 to 165</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">166 to 278</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">279 to 390</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">391 to 503</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Methadone (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 to 44</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">45 to 74</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75 to 104</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">105 to 134</p></td></tr>\n        <tr>\n          <td></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Fentanyl transdermal recommended dose (mcg/h) </b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>25 mcg/h</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>50 mcg/h</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>75 mcg/h</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>100 mcg/h</b></p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:0em;margin-top:2em;\">Transdermal patch (Duragesic): Canadian labeling: Adults:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Canadian Labeling: Dose Conversion Guidelines (Adults): Recommended Initial Duragesic Dose Based Upon Daily Oral Morphine Dose<sup>1,2</sup></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Oral 24-Hour Morphine</p>\n            <p style=\"text-indent:0em;\">(Current Dose in mg/day)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duragesic Dose</p>\n            <p style=\"text-indent:0em;\">(Initial Dose in mcg/h)</p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>1</sup>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>2</sup>Recommendations are based on Canadian product labeling for Duragesic.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <b>Note:</b> The 12 mcg/hour dose included in this table is to be used for incremental dose adjustment and is generally not recommended for initial dosing, except for patients in whom lower starting doses are deemed clinically appropriate.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">45 to 59</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 134</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">135 to 179</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">37</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">180 to 224</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">225 to 269</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">62</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">270 to 314</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">315 to 359</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">87</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">360 to 404</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">405 to 494</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">495 to 584</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">585 to 674</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">175</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">675 to 764</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">765 to 854</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">225</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">855 to 944</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">945 to 1,034</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">275</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,035 to 1,124</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Canadian Labeling: Dosing Conversion Guidelines (Adults)<sup>1,2</sup></caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Current Analgesic</p></th>\n          <th colspan=\"7\" align=\"center\">\n            <p style=\"text-indent:0em;\">Daily Dosage</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"8\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>\n        <tr>\n          <td colspan=\"8\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>Recommendations are based on Canadian product labeling for Duragesic.</p></td></tr>\n        <tr>\n          <td colspan=\"8\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>3</sup>Morphine dose conversion based upon I.M to oral dose ratio of 1:3.</p></td></tr>\n        <tr>\n          <td colspan=\"8\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>4</sup>Insufficient data available to provide specific dosing recommendations. Use caution; adjust dose conservatively.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Morphine<sup>3</sup></p>\n            <p style=\"text-indent:0em;\">(IM/IV)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 to 44</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">45 to 60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">61 to 75</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">76 to 90</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">n/a<sup>4</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">n/a<sup>4</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">n/a<sup>4</sup></p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Oxycodone</p>\n            <p style=\"text-indent:0em;\">(oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 66</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">67 to 90</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">91 to 112</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">113 to 134</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">135 to 157</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">158 to 179</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">180 to 202</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Codeine</p>\n            <p style=\"text-indent:0em;\">(oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 to 447</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">448 to 597</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">598 to 747</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">748 to 897</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">898 to 1,047</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,048 to 1,197</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,198 to 1,347</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Hydromorphone</p>\n            <p style=\"text-indent:0em;\">(oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 16</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">17 to 22</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">23 to 28</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">29 to 33</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">34 to 39</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 to 45</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">46 to 51</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Hydromorphone</p>\n            <p style=\"text-indent:0em;\">(IV)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 8.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.5 to 11.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11.5 to 14.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">14.5 to 16.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16.6 to 19.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">19.6 to 22.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">22.6 to 25.5</p></td></tr>\n        <tr>\n          <td></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Fentanyl transdermal recommended dose</b></p>\n            <p style=\"text-indent:0em;\">\n              <b>(mcg/h)</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>25 mcg/h</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>37 mcg/h</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>50 mcg/h</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>62 mcg/h</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>75 mcg/h</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>87 mcg/h</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>100 mcg/h</b></p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170639\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fentanyl-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fentanyl: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Ranges listed may not represent the maximum doses that may be required in some patients. Doses and dosage intervals should be titrated to pain relief/prevention. Monitor vital signs routinely. Single IM doses have duration of 1 to 2 hours, single IV doses last 0.5 to 1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Surgery adjunct to anesthesia (induction and maintenance):</b> Children 2 to 12 years: IV, IM: 2 to 3 mcg/<b>kg</b>/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breakthrough cancer pain: </b> Adolescents &ge;16 years: Transmucosal lozenge (Actiq): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic pain management:</b> Children &ge;2 years and Adolescents (opioid-tolerant patients): Transdermal patch (US labeling): Refer to adult dosing. <b>Note:</b> Canadian labeling does not approve of use in patients &lt;18 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management (off-label use):</b> <i>Patient-controlled analgesia (PCA) (off-label use; American Pain Society, 2008): </i> Children &lt;50 kg: IV: <b>Note: </b>Opioid-naive:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual concentration: 10 to 50 mcg/mL (varies by patient weight and institution)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Demand dose: 0.5 to 1 mcg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lockout interval: 6 to 8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual basal rate (optional): &le;0.5 mcg/kg/<b>hour</b>. <b>Note:</b> Due to safety concerns, continuous basal infusions are not recommended for initial programming and should rarely be used (Grass, 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170616\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Elderly have been found to be twice as sensitive as younger patients to the effects of fentanyl. A wide range of doses may be used. When choosing a dose, take into consideration the following patient factors: age, weight, physical status, underlying disease states, other drugs used, type of anesthesia used, and the surgical procedure to be performed. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">Transmucosal lozenge (eg, Actiq): In clinical trials, patients who were &gt;65 years of age were titrated to a mean dose that was 200 mcg less than that of younger patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14936198\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal (device): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); fentanyl pharmacokinetics may be altered in renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal (patch): Degree of impairment (ie, CrCl) not defined in manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild-to-moderate impairment: Initial: Reduce dose by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and intranasal: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution. Although fentanyl pharmacokinetics may be altered in renal disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Doses should be titrated to reach clinical effect with careful monitoring of patients with severe renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170617\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal (device): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); fentanyl pharmacokinetics may be altered in hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal (patch):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild-to-moderate impairment: Initial: Reduce dose by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and intranasal: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution. Although fentanyl pharmacokinetics may be altered in hepatic disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Doses should be titrated to reach clinical effect with careful monitoring of patients with severe hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170583\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Film, for buccal application, as citrate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Onsolis: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s) [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution, as citrate [strength expressed as base, preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublimaze: 100 mcg/2 mL (2 mL); 250 mcg/5 mL (5 mL); 1000 mcg/ 20 mL (20 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 100 mcg/2 mL (2 mL); 250 mcg/5 mL (5 mL); 500 mcg/10 mL (10 mL); 1000 mcg/ 20 mL (20 mL); 2500 mcg/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid, sublingual, as base [spray]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subsys: 100 mcg (30s); 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s) [contains dehydrated ethanol 63.6%, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lozenge, oral, as citrate [strength expressed as base, transmucosal]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Actiq: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s); 1600 mcg (30s) [contains sugar 2 g/lozenge; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s); 1600 mcg (30s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch, transdermal, as base:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 12 [delivers 12.5 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2</sup>; 5 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 25 [delivers 25 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2</sup>; 10 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 50 [delivers 50 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2</sup>; 20 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 75 [delivers 75 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2</sup>; 30 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 100 [delivers 100 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2; </sup>40 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ionsys: 40 mcg/actuation (6s) [iontophoretic transdermal system]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 12 [delivers 12.5 mcg/hr] (5s); 25 [delivers 25 mcg/hr] (5s); 37.5 [delivers 37.5 mcg/hr]; 50 [delivers 50 mcg/hr] (5s); 62.5 [delivers 62.5 mcg/hr]; 75 [delivers 75 mcg/hr] (5s); 87.5 [delivers 87.5 mcg/hr] (5s); 100 [delivers 100 mcg/hr] (5s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder, for prescription compounding, as citrate: USP: 100% (1 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, intranasal, as citrate [strength expressed as base, spray]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lazanda: 100 mcg/spray (5 mL); 300 mcg/spray (5 mL); 400 mcg/spray (5 mL) [delivers 8 metered sprays]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, for buccal application, as citrate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fentora: 100 mcg (28s); 200 mcg (28s); 400 mcg (28s); 600 mcg (28s); 800 mcg (28s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, sublingual, as citrate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Abstral: 100 mcg (12s, 32s); 200 mcg (12s, 32s); 300 mcg (12s, 32s); 400 mcg (12s, 32s); 600 mcg (32s); 800 mcg (32s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170567\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Injection, lozenge, patch</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10461326\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch, transdermal, as base: 37 mcg/hr (5s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106456\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Onsolis: Reformulated product FDA approved August 2015; availability anticipated in the first half of 2018.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170661\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50183666\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As a requirement of the REMS program, access is restricted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transmucosal immediate-release fentanyl products (eg, sublingual tablets and spray, oral lozenges, buccal tablets and soluble film, intranasal) are only available through the Transmucosal Immediate-Release Fentanyl (TIRF) REMS ACCESS program. Enrollment in the program is required for outpatients, prescribers for outpatient use, pharmacies (inpatient and outpatient), and distributors. Enrollment is not required for inpatient administration (eg, hospitals, hospices, long-term care facilities), inpatients, and prescribers who prescribe to inpatients. Further information is available at 1-866-822-1483 or at www.TIRFREMSaccess.com</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Effective December, 2011, individual REMs programs for TIRF products were combined into a single access program (TIRF REMS Access). Prescribers and pharmacies that were enrolled in at least one individual REMS program for these products will automatically be transitioned to the single access program.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874432\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Abstral: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022510s015lbl.pdf#page=29&amp;token=hSs1Eazyf+PPIFqHUHqt7Rx7EzEIIMJVvMb5euj3IZNBkEtTNuIcbYAnyP/Znjt+p4+CfjxreohMc+/zp4t1lN7jMXe1BfvBKowHE4PmrMtvfEt1q416e7o7vtNxvxPl&amp;TOPIC_ID=8441\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022510s015lbl.pdf#page=29</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Actiq: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020747s043s044lbl.pdf#page=21&amp;token=HN1Y7iaI/cfwN0CEMuhl60FCjkhA5QGAwZVHV8hlo6MNxyaKbWD6dM6d1G/Jr6xfL3Y8pqAWIHeE0mNDkupOYh2Swn/AH5dHQqC5Vix8dFP8fQ+h1YiTEJEiKubT32pG&amp;TOPIC_ID=8441\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020747s043s044lbl.pdf#page=21</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019813s072s073lbl.pdf#page=48&amp;token=7ZzLF+C7R96qd+gtCVwN2M+JMxhUBgOqvOTzTEIWQ1U5ZH65UNzdgSIcG1wPlB8SAZtrzEAylgfTg7jTwpuyynBNYN5Zx19iWRozZQL72ibCcfdGlMpp2ekFcYIbyObE&amp;TOPIC_ID=8441\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019813s072s073lbl.pdf#page=48</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fentora: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021947s019lbl.pdf#page=20&amp;token=sgue1VRxbi89Ggz7GyoGb6HTtAtcgb+mY0GLaPEoKnyaAkcNZuI4VWU0HaUvvqqpRyKkCLlGPWN6+sZKcFTtwqWiPZr0tw7k4dWOM0LERHT+mF/C8/hzyjf5FwGyNXc8&amp;TOPIC_ID=8441\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021947s019lbl.pdf#page=20</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lazanda: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022569s024lbl.pdf#page=35&amp;token=rCuM9yf0Q5zu9voZMjQfPRhajnsn9tWo3hZU/RrAlTt3j74C184qWW4cE7DthHvNnNqL2sl48rM+1SuP2JgIJZmPqIruD76PFevNfDOx7QbWApyOCurZkuiqYeQCtpDR&amp;TOPIC_ID=8441\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022569s024lbl.pdf#page=35</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Onsolis: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022266s017s018lbl.pdf#page=32&amp;token=uV9lFmKDxTSyBGHQ5zKMG2kn6tzpSAfjLKdcE79iVIzgsDr6hlJSEmgjGOxY0edeHUKhlKht1SfjSnitHyi4UmbqeKUJbOUHIgPeqFP9KmYItrsH4VClS4vxTFMb8tk+&amp;TOPIC_ID=8441\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022266s017s018lbl.pdf#page=32</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subsys: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202788s016lbl.pdf#page=38&amp;token=6Y5kOx6/9dAbqNB3qpFkVY0T/8Ru6wysVStG0u/Vc7fZ2As111CgRFLet0k2ApCmJLFWzDwFbfqL5jv0r0LxqIciMUH6MwzcrCTNQV6Q5etWWU4WCmlF3wUJpBBvyJ2T&amp;TOPIC_ID=8441\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202788s016lbl.pdf#page=38</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170587\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epidural (Canadian labeling; not in US labeling): For postoperative pain management may administer as bolus dose (diluted in preservative free NS to a final concentration of 10 mcg/mL) or by continuous infusion at a rate of 1 mcg/kg/hour. Use within 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer IM or IV slowly over 1 to 2 minutes; rapid IV infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest. May also administer by continuous infusion or PCA (off-label use).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal device (eg, Ionsys): Always wear gloves when handling the device. Avoid contact with synthetic materials (such as carpeted flooring) while assembling and avoid exposing the device to electronic security systems. Prior to administration, clip excessive hair from application site if necessary (do not shave); clean the site with alcohol and let dry; do not use soaps, lotions, or other agents. Apply one device to healthy, unbroken/intact, non-irritated, and non-irradiated skin on the chest or upper outer arm only. Allow only the patient to self-administer doses; each on-demand dose is delivered over a 10-minute period. Each device operates up to 24 hours or 80 doses, whichever comes first. After 24 hours have elapsed, or 80 doses have been delivered, the device will not deliver any additional doses; if the patient tries to initiate a dose, the device will ignore the dose request. Ionsys may be used for a maximum of 72 hours, with each subsequent device applied to a different skin site. Refer to manufacturer&rsquo;s labeling for complete activation, administration, and removal instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch (eg, Duragesic): Apply to nonirritated and nonirradiated skin on a flat surface, such as chest, back, flank, or upper arm; apply to the upper back in young children and patients with cognitive impairment. Hair at application site may be clipped (do not shave). If application site must be cleaned prior to application, clean site with clear water and allow to dry completely. Do not use damaged, cut or leaking patches; patch may be less effective. Do not use soaps, oils, lotions, alcohol, or any other agents to cleanse skin before application because they may irritate the skin or alter its characteristics. Immediately after removal from sealed package, firmly press patch in place and hold for 30 seconds. Wash hands immediately with soap and water after applying patch. Change patch every 72 hours; apply new patch to a different skin site. Contact with unwashed or unclothed application sites can result in secondary exposure to fentanyl and should be avoided. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, tanning lamps, hot tub, sunbathing, saunas, heated water beds). If there is difficulty with patch adhesion, the edges of the system may be taped in place with first-aid tape. If there is continued difficulty with adhesion, an adhesive film dressing (eg, Bioclusive, Tegaderm) may be applied over the system. Dispose of any used or unused patches by removing patch from protective pouch and liner, fold adhesive ends together and flush patch down toilet immediately. Do not flush pouch or protective liner as such items can be discarded in the trash. For used and unused patches, the Canadian labeling recommends folding adhesive ends together and returning to a pharmacy for proper disposal; temporary storage in a biohazard container may be used before returning to pharmacy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lozenge: Foil overwrap should be removed just prior to administration. Place the unit in mouth between the cheek and gum and allow it to dissolve. Do not chew. Lozenge may be moved from one side of the mouth to the other using the handle. The unit should be consumed over a period of 15 minutes. After consumption of a complete unit, the handle may be disposed of in a trash container that is out of the reach of children. For a unit that still has any drug matrix remaining on the handle, the handle should be placed under hot running tap water until the entire drug matrix has dissolved. Special child-resistant containers are available to temporarily store partially consumed units that cannot be disposed of immediately. Refer to manufacturer&rsquo;s labeling for additional disposal instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buccal film: Foil overwrap should be removed just prior to administration. Prior to placing film, wet inside of cheek using tongue or by rinsing with water. Place film inside mouth with the pink side of the unit against the inside of the moistened cheek. With finger, press the film against cheek and hold for 5 seconds. The film should stick to the inside of cheek after 5 seconds. The film should be left in place until it dissolves (usually within 15-30 minutes after application). Liquids may be consumed after 5 minutes of application. Food can be eaten after film dissolves. If using more than 1 film simultaneously (during titration period), apply films on either side of mouth (do not apply on top of each other). Do not chew or swallow film. Do not cut or tear the film. All patients must initiate therapy using the 200 mcg film. To dispose of film; remove foil overwrap from any unused, unneeded films and dispose by flushing down the toilet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buccal tablet: Patient should not open blister until ready to administer. The blister backing should be peeled back to expose the tablet; tablet should not be pushed out through the blister. Immediately use tablet once removed from blister. Place entire tablet in the buccal cavity (above a rear molar, between the upper cheek and gum) or under the tongue (US labeling recommends for maintenance dosing only; Canadian labeling does not restrict sublingual use to maintenance dosing only); should dissolve in about 14 to 25 minutes. If remnants remain after 30 minutes, they may be swallowed with water. Tablet should not be split, crushed, sucked, chewed, or swallowed whole. When possible, alternate sides of mouth with each dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Prior to initial use, prime device by spraying 4 sprays into the provided pouch (the counting window will show a green bar when the bottle is ready for use). Insert nozzle a short distance into the nose (~<sup>1</sup>/<sub>2</sub> inch or 1 cm) and point towards the bridge of the nose (while closing off the other nostril using 1 finger). Press on finger grips until a &ldquo;click&rdquo; sound is heard and the number in the counting window advances by one. The &ldquo;click&rdquo; sound and dose counter are the only reliable methods for ensuring a dose has been administered (spray is not always felt on the nasal mucosa). Patient should remain seated for at least 1 minute following administration. Do not blow nose for &ge;30 minutes after administration. Wash hands before and after use. If not used within 5 days, re-prime by spraying once. There are 8 full therapeutic sprays in each bottle; do not continue to use bottle after &ldquo;8&rdquo; sprays have been used. Dispose of bottle and contents if it has been &ge;60 days since first use. Before disposal, all unopened or partially used bottles must be completely emptied by spraying the contents into the provided pouch. After &ldquo;8&rdquo; therapeutic sprays has been reached on the counter, patients should continue to spray an additional four sprays into the pouch to ensure that any residual fentanyl has been expelled (an audible click will no longer be heard and the counter will not advance beyond &ldquo;8&rdquo;). The empty bottle and the sealed pouch must be put into the child-resistant container before placing in the trash. Wash hands with soap and water immediately after handling the pouch. If the pouch is lost, another one can be ordered by the patient or caregiver by calling 1-866-458-6389.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual spray: Open sealed blister unit with scissors immediately prior to administration. Contents of unit should be sprayed into mouth under the tongue. Dispose of each unit dose immediately after use; place used unit into one of the provided white disposal bags. After sealing appropriately, discard in the trash. Dispose of any unused units as soon as no longer needed. Prior to disposal, empty all the medicine into the provided charcoal-lined disposal pouch. The disposal pouch should then be placed into the white disposal bag, sealed appropriately, and discarded in the trash.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet: Remove from the blister unit immediately prior to administration. Place tablet directly under the tongue on the floor of the mouth and allow to completely dissolve; do not chew, suck, or swallow. Do not eat or drink anything until tablet is completely dissolved. In patients with a dry mouth, water may be used to moisten the buccal mucosa just before administration. To dispose of sublingual tablets; remove any unused tablets from the blister cards and dispose by flushing down the toilet. In Canada, it is recommended that unused tablets be disposed of via a pharmacy take back program.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472636\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472637\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170586\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Injection:</b></i> <b>Surgery:</b> Adjunct to general or regional anesthesia; preoperative medication; analgesic during anesthesia and in the immediate postoperative period.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Transdermal device (eg, Ionsys):</i> Postoperative pain, acute:</b> Short-term management of acute postoperative pain severe enough to require an opioid analgesic in the hospital and for which alternative treatments are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Reserve for use in patients for whom alternative treatment options (eg, nonopioid analgesics) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Only for use in patients who are alert enough and have adequate cognitive ability to understand the directions for use. Not for home use. Transdermal device is for use only in patients in the hospital. Discontinue treatment with the device before patients leave the hospital. The device is for use after patients have been titrated to an acceptable level of analgesia using alternate opioid analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Transdermal patch (eg, Duragesic):</b></i> <b>Chronic pain:</b> Management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Reserve for use in patients for whom alternative treatment options (eg, nonopioid analgesics, immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Not indicated as an as-needed analgesic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Transmucosal lozenge (eg, Actiq), buccal tablet (Fentora), buccal film (Onsolis), intranasal (Lazanda), sublingual tablet (Abstral), sublingual spray (Subsys):</b></i> <b>Cancer pain:</b> Management of breakthrough cancer pain in opioid-tolerant patients &ge;18 years (Abstral, Fentora, Lazanda, Onsolis, Subsys) and &ge;16 years (Actiq) who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Not for use in opioid non-tolerant patients. Not for use in the management of acute or postoperative pain, including headache/migraine, dental pain, or in the emergency department. As a part of the TIRF REMS Access program, these products may be dispensed only to outpatients enrolled in the program. For inpatient administration (eg, hospitals, hospices, and long-term care facilities that prescribe for inpatient use), patient and prescriber enrollment is not required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> &quot;Opioid-tolerant&quot; patients are defined as patients who are taking at least:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral morphine 60 mg/day, <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal fentanyl 25 mcg/hour, <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral oxycodone 30 mg/day, <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral hydromorphone 8 mg/day, <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral oxymorphone 25 mg/day, <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral hydrocodone 60 mg/day, <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Equianalgesic dose of another opioid for at least 1 week</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170670\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FentaNYL may be confused with alfentanil, SUFentanil</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fentanyl transdermal system patches: Leakage of fentanyl gel from the patch has been reported; patch may be less effective; do not use. Thoroughly wash any skin surfaces coming into direct contact with gel with water (do not use soap). May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fentanyl transdermal system patches: </p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Dosing of transdermal fentanyl patches may be confusing. Transdermal fentanyl patches should always be prescribed in mcg/hour, not size. Patch dosage form of Duragesic-12 actually delivers 12.5 mcg/hour of fentanyl. Use caution, as orders may be written as &ldquo;Duragesic 12.5&rdquo; which can be erroneously interpreted as a 125 mcg dose.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patches should be stored and disposed of with care to avoid accidental exposure to children. The FDA has issued numerous safety advisories to warn users of the possible consequences (including hospitalization and death) of inappropriate storage or disposal of patches.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Abstral, Actiq, Fentora, Onsolis, and Subsys are not interchangeable; do not substitute doses on a mcg-per-mcg basis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170574\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Confusion, dizziness, drowsiness, fatigue, headache, sedation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site erythema (transdermal device)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation, bigeminy, cardiac arrhythmia, chest pain, deep vein thrombosis, edema, hypertension, hypotension, myocardial infarction, orthostatic hypotension, palpitations, peripheral edema, pulmonary embolism (nasal spray), sinus tachycardia, syncope, tachycardia, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal dreams, abnormal gait, abnormality in thinking, agitation, altered sense of smell, amnesia, anxiety, ataxia, chills, depression, disorientation, dysphoria, euphoria, hallucination, hypertonia, hypoesthesia, hypothermia, insomnia, irritability, lack of concentration, lethargy, malaise, mental status changes, migraine, nervousness, neuropathy, paranoia, paresthesia, restlessness, speech disturbance, stupor, vertigo, withdrawal syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia, cellulitis, decubitus ulcer, diaphoresis, erythema, exfoliation of skin (application site, transdermal device), hyperhidrosis, local papules (application site, transdermal device), night sweats, pallor, papule, pruritus, pustules (application site, transdermal device), skin rash, vesicobullous rash (application site, transdermal device)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash, hypercalcemia, hyperglycemia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention, abdominal pain, anorexia, decreased appetite, diarrhea, dysgeusia, dyspepsia, dysphagia (buccal tablet/film/sublingual spray), flatulence, gastritis, gastroenteritis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal ulcer (gingival, lip, mouth; transmucosal use/nasal spray), gingival pain (buccal tablet), gingivitis (lozenge), glossitis (lozenge), hematemesis, intestinal obstruction, periodontal abscess (lozenge/buccal tablet), rectal pain, stomatitis (lozenge/buccal tablet/sublingual tablet/sublingual spray), tongue disease (sublingual tablet), xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary retention (3%), difficulty in micturition, dysuria, erectile dysfunction, mastalgia, urinary incontinence, urinary tract infection, urinary urgency, vaginal hemorrhage, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (3%), bruise, leukopenia, lymphadenopathy, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Ascites, increased serum alkaline phosphatase, increased serum AST, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site burning (transdermal device), application site discharge (transdermal device), application site edema (transdermal device), application site irritation, application site itching (transdermal device), application site pain, application site rash (transdermal device), application site vesicles (transdermal device)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, leg cramps, limb pain, myalgia, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blepharoptosis, blurred vision, diplopia, dry eye syndrome, strabismus, swelling of eye, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea, asthma, atelectasis, bronchitis, cough, dyspnea (exertional), epistaxis, flu-like symptoms, hemoptysis, hyperventilation, hypoventilation, hypoxia, laryngitis, nasal congestion (nasal spray), nasal discomfort (nasal spray), nasopharyngitis, pharyngitis, pharyngolaryngeal pain, pneumonia, postnasal drip (nasal spray), rhinitis, rhinorrhea (nasal spray), sinusitis, upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever, wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Allergic dermatitis, anaphylactoid reaction, anaphylaxis, angina pectoris, bradycardia, bronchoconstriction, candidiasis, chest wall rigidity, clonus, contact dermatitis, crusted skin, cyanosis, decreased libido, dental caries, dermatitis, drug dependence (physical and psychological; with prolonged use), eczema, emotional lability, eructation, esophageal stenosis, exfoliative dermatitis, falling, fecal impaction, flank pain, flushing, genitourinary tract spasm, gingival hemorrhage, gum line erosion, hematuria, hiccups, hostility, hyperesthesia, hypoglycemia, hypogonadism (Brennan 2013; Debono 2011), impaired consciousness, increased bronchial secretions, joint swelling, local hemorrhage, local hypersensitivity reaction, localized infection, local skin hyperpigmentation (lasted 2 to 3 weeks), local tissue necrosis, loss of consciousness, miosis, muscle rigidity (transient; observed in infants whose mothers were treated with IV fentanyl), muscle spasm, muscle twitching, myasthenia, nocturia, oliguria, pancytopenia, pleural effusion, polyuria, respiratory depression, respiratory distress, seizure, sexual disorder, skin erosion, Stevens-Johnson syndrome, swelling, swollen tongue, tonic-clonic seizures, tooth loss, upper abdominal pain, urticaria, voice disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170590\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis, hypersensitivity) to fentanyl or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for transdermal device (Ionsys): Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); hypersensitivity to cetylpyridinium chloride (eg, Cepacol).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for transdermal patch (Duragesic): Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); patients requiring short-term therapy, management of acute or intermittent pain, postoperative or mild pain; patients who are <b>not</b> opioid tolerant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for transmucosal buccal tablets (Fentora), buccal films (Onsolis), lozenges (Actiq), sublingual tablets (Abstral), sublingual spray (Subsys), intranasal (Lazanda): Significant respiratory depression (Actiq, Fentora only); acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); acute or postoperative pain (including headache, migraine, or dental pain); patients who are <b>not</b> opioid tolerant; acute pain management in the emergency room.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindication (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Septicemia; severe hemorrhage or shock; local infection at proposed injection site; disturbances in blood morphology and/or anticoagulant therapy or other concomitant drug therapy or medical conditions which could contraindicate the technique of epidural administration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablets (Abstral): Severe bronchial asthma, chronic obstructive airway, or status asthmaticus; acute respiratory depression; hypercapnia; cor pulmonale; known or suspected mechanical GI obstruction (eg, bowel obstruction or strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); mild pain that can be managed with other pain medications; acute pain management other than breakthrough or postoperative pain (including headache or migraine, dental pain or emergency room use); acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use or use within 14 days of a monoamine oxidase (MAO) inhibitor; breastfeeding women; during labor and delivery; opioid-nontolerant patients (including patients on intermittent or as needed opioid dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch: Hypersensitivity to other opioids; suspected surgical abdomen (eg, acute appendicitis, pancreatitis); known or suspected mechanical GI obstruction (eg, bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use of MAO inhibitors or within 14 days of therapy; perioperative pain; women who are nursing, pregnant, or during labor and delivery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal buccal tablets (Fentora): Hypersensitivity to other opioids; acute pain management in the emergency room; known or suspected mechanical GI obstruction (eg, bowel obstruction or strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); acute or severe bronchial asthma, chronic obstructive airway, status asthmaticus; acute respiratory depression; hypercapnia; cor pulmonale; acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use or use within 14 days of an MAO inhibitor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170571\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur, including following use in opioid non-tolerant patients and improper dosing. Monitor closely for respiratory depression, especially during initiation or dose escalation.</b> Abstral, Actiq, Duragesic, Fentora, Lazanda, Onsolis, or Subsys should only be prescribed for opioid-tolerant patients. Risk of respiratory depression usually occurs after administration of initial dose in nontolerant patients or when given with other drugs that depress respiratory function. Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: May occur with concomitant use of serotonergic agents (eg, SSRIs, SNRIs, triptans, TCAs), lithium, St John&rsquo;s wort, agents that impair metabolism of serotonin (eg, MAO inhibitors), or agents that impair metabolism of tramadol (eg, CYP2D6 and 3A4 inhibitors). Monitor patients for symptoms of serotonin syndrome such as mental status changes (eg, agitation, hallucinations, coma); autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia); neuromuscular changes (eg, hyperreflexia, incoordination); and/or GI symptoms (eg, nausea, vomiting, diarrhea).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic rhinitis: Intranasal: Allergic rhinitis is not expected to alter fentanyl absorption following nasal administration; however, use of nasal decongestants (eg, oxymetazoline) during episodes of rhinitis may result in lower peak concentrations and delayed T<sub>max</sub>, therefore, titration of intranasal fentanyl is not recommended during use of nasal decongestants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; may cause constriction of sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia: Use with caution in patients with bradycardia or bradyarrhythmias (may produce further bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Avoid transdermal (patch) in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral mucositis: Sublingual spray (Subsys): Cancer patients with oral mucositis experienced increased fentanyl exposure following sublingual spray administration; avoid use in patients with grade 2 or higher mucositis; use with caution in patients with grade 1 mucositis, and closely monitor for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Avoid transdermal (patch) in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with a history of seizure disorders; may cause or exacerbate seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: <b>[US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of oxycodone/acetaminophen and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP3A4 interactions: <b>[US Boxed Warning]: The concomitant use of fentanyl with all cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in fentanyl plasma concentration. Monitor patients receiving fentanyl and any CYP3A4 inhibitor or inducer.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose. Use opioids for chronic pain with caution in this age group; monitor closely due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (Dowell [CDC 2016]). Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: <b>[US Boxed Warning]:</b> <b>Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. </b>Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. Onset, duration and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Buccal film, buccal tablet, intranasal, sublingual tablet, sublingual spray, and lozenge:<b> [US Boxed Warning]: Preparations contain an amount of medication that can be fatal to children. Keep all used and unused products out of the reach of children at all times and discard products properly.</b> Patients and caregivers should be counseled on the dangers to children including the risk of exposure to partially-consumed products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: IV: Inject slowly over 1 to 2 minutes; rapid IV infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest; nondepolarizing skeletal muscle relaxant may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Transmucosal and nasal fentanyl formulations are contraindicated in the management of acute or postoperative pain and in opioid nontolerant patients.</b> Should be used only for the care of opioid-tolerant cancer patients with breakthrough pain and is intended for use by specialists who are knowledgeable in treating cancer pain.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Substantial differences exist in the pharmacokinetic profile of fentanyl products that result in clinically important differences in the extent of absorption of fentanyl. When prescribing or dispensing fentanyl, do not convert patients on a mcg-per-mcg basis from one fentanyl product to another fentanyl product; the substitution of one fentanyl product for another fentanyl product may result in a fatal overdose.</b> <b>Death has been reported in children who have accidentally ingested transmucosal immediate-release fentanyl products. Strict adherence to the recommended handling and disposal instructions is of the utmost importance to prevent accidental exposure.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Available only through the TIRF REMS ACCESS program, a restricted distribution program with outpatients, prescribers who prescribe to outpatients, pharmacies (inpatient and outpatient), and distributor-required enrollment.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Application site reactions, ranging from paresthesia to ulcerations and bleeding, occurred with buccal tablet (Fentora).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal iontophoretic system (Ionsys):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Ionsys REMS Program.</b> <b>Healthcare facilities that dispense Ionsys must be certified in this program and comply with the REMS requirements.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>- [US Boxed Warning]: For use only in patients in the hospital. Discontinue treatment before patients leave the hospital. Only the patient should activate Ionsys dosing. Accidental exposure to an intact Ionsys device or to the hydrogel component, especially by children, can result in a fatal overdose of fentanyl.</b> Following accidental contact with the device or its components, immediately rinse the affected area thoroughly with water. Do not use soap, alcohol, or other solvent because they may enhance the drug&rsquo;s ability to penetrate the skin; monitor for signs of respiratory or CNS depression. If the device is not handled correctly using gloves, healthcare professionals are at risk of accidental exposure to a fatal overdose of fentanyl.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Ionsys device is considered magnetic resonance unsafe. The device contains metal parts and must be removed and properly disposed of before an MRI procedure to avoid injury to the patient and damage to device. It is unknown if exposure to an MRI procedure increases release of fentanyl from the device. Monitor any patients wearing the device with inadvertent exposure to an MRI for signs of CNS and respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Use of Ionsys device during cardioversion, defibrillation, X-ray, CT, or diathermy can damage the device from the strong electromagnetic fields set up by these procedures. The device contains radio-opaque components and may interfere with an X-ray image or CT scan. Remove and properly dispose of the device prior to cardioversion, defibrillation, X-ray, CT, or diathermy. Avoid contact with synthetic materials (such as carpeted flooring) to reduce the possibility of electrostatic discharge and damage to the device. Avoid exposing the device to electronic security systems to reduce the possibility of damage. Use near communications equipment (eg, base stations for radio telephones and land mobile radios, amateur radio, AM and FM radio broadcast and TV broadcast Radio) and Radio Frequency Identification (RFID) transmitters can damage the device. Depending on the rated maximum output power and frequency of the transmitter, the recommended separation distance between the device and communications equipment or the RFID transmitter ranges between 0.12 and 23 meters. The low-level electrical current provided by the device does not result in electromagnetic interference with other electromechanical devices like pacemakers or electrical monitoring equipment. If exposure to the procedures listed above, electronic security systems, electrostatic discharge, communications equipment, or RFID transmitters occurs, and if the device does not appear to function normally, remove and replace with a new device.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Topical skin reactions (erythema, sweating, vesicles, papules/pustules) may occur with use and are typically limited to the application site area. If a severe skin reaction is observed, remove device and discontinue further use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Transdermal patch is contraindicated for use as an as-needed analgesic, in acute or postoperative pain, or in patients who are opioid nontolerant. Monitor closely for respiratory depression during use, particularly during initiation of therapy or after dose increases.</b> Should only be prescribed by health care professionals who are knowledgeable in the use of potent opioids in the management of chronic pain.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Exposure of application site and surrounding area to direct external heat sources (eg, heating pads, electric blankets, heat or tanning lamps, sunbathing, hot baths, hot tubs, heated water beds, saunas) may increase fentanyl absorption and has resulted in fatalities.</b> <b>Warn patients to avoid exposing the application site and surrounding area to direct external heat sources.</b> Serum fentanyl concentrations may increase by approximately one-third for patients with a body temperature of 40&deg;C (104&deg;F) secondary to a temperature-dependent increase in fentanyl release from the patch and increased skin permeability.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Deaths due to a fatal overdose of fentanyl have occurred when children and adults were accidentally exposed to fentanyl transdermal patch. Strict adherence to recommended handling and disposal instructions is necessary to prevent accidental exposures.</b> Avoid unclothed/unwashed application site exposure, inadvertent person-to-person patch transfer (eg, while hugging), incidental exposure (eg, sharing same bed, sitting on patch), intentional exposure (eg, chewing), or accidental exposure by caregivers when applying/removing patch.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Should be applied only to intact skin. Use of a patch that has been cut, damaged, or altered in any way may result in overdosage. Patients who experience adverse reactions should be monitored for at least 24 hours after removal of the patch. Drug continues to be absorbed from the skin for 24 hours or more following removal of the patch. May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion:<b> [US Boxed Warning]: Use exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient&rsquo;s risk prior to prescribing fentanyl and monitor all patients regularly for the development of these behaviors and conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with increased risk include younger age and psychotropic medication use. Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (&ge;50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental exposure: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially by children, can result in a fatal overdose of fentanyl. Fentanyl must be kept out of reach of children.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults: Opioids should not be used as first-line therapy for chronic pain management (pain &gt;3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder). Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg. NSAIDs, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and non-opioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages. Risks and benefits should be re-evaluated when increasing dosage to &ge;50 morphine milligram equivalents (MME)/day orally; dosages &ge;90 MME/day orally should be avoided unless carefully justified (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Opioids decrease bowel motility; monitor for decreased bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms. Taper dose gradually when discontinuing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170653\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170576\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8441&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): May decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: May decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.<b> Exceptions: </b>Midodrine; Naphazoline (Ophthalmic); Phenylephrine (Ophthalmic); Phenylephrine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiplatelet Agents (P2Y12 Inhibitors): FentaNYL may diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Opioids (Anilidopiperidine) may enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Opioids (Anilidopiperidine) may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Opioids (Anilidopiperidine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Opioid Analgesics. Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: May increase the serum concentration of FentaNYL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of FentaNYL.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of FentaNYL.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of FentaNYL. Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of FentaNYL. Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of FentaNYL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: FentaNYL may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of FentaNYL. Management: Avoid fentanyl during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: FentaNYL may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of FentaNYL. Management: Monitor for increased opioid effects/toxicities if these agents are combined. Consider using lower initial doses of fentanyl. Canadian labeling recommends avoidance of this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of FentaNYL.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170606\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Fentanyl concentrations may be increased by grapefruit juice. Management: Avoid concurrent intake of large quantities (&gt;1 quart/day) of grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170578\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170593\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in some animal reproduction studies. Fentanyl crosses the placenta.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Fentanyl injection may be used for the management of pain during labor (ACOG 2002). When used for pain relief during labor, opioids may temporarily affect the heart rate of the fetus (ACOG 2002). Transient muscular rigidity has been observed in the neonate with fentanyl; symptoms of respiratory or neurological depression were not different than those observed in infants of untreated mothers.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>[US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. </b>If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur; monitoring of the neonate is recommended. The minimum effective dose should be used if opioids are needed (Chou 2009). Symptoms characteristic of neonatal abstinence syndrome have been observed following chronic fentanyl use in pregnant women. Neonatal abstinence syndrome following opioid exposure may present with autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, increased muscle tone, irritability, seizure, tremor) symptoms (Dow 2012; Hudak 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction or infertility (Brennan 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Transdermal patch (Duragesic), transdermal iontophoretic system (Ionsys), transmucosal lozenge (Actiq), intranasal (Lazanda), sublingual tablet (Abstral), sublingual spray (Subsys), buccal tablet (Fentora), and buccal film (Onsolis) are not recommended for analgesia during labor and delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170594\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fentanyl is present in low concentrations in breast milk and breastfeeding is not recommended by most manufacturers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Parenteral opioids used during labor have the potential to interfere with a newborn's natural reflex to breastfeed within the first few hours after birth. When needed, a short-acting opioid, such as fentanyl, is preferred for women who will be breastfeeding (Montgomery 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Breastfeeding is considered acceptable following single doses to the mother; however, limited information is available when used long-term (Spigset, 2000). Breastfeeding infants exposed to large doses of opioids should be monitored for apnea and sedation (Montgomery 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170595\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Transmucosal lozenge contains 2 g sugar per unit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170580\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pain relief; respiratory and mental status, blood pressure, heart rate; signs of misuse, abuse, or addiction; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch: Monitor for 24 hours after application of first dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate recommendations: Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and re-checking should be considered at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170570\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds with stereospecific receptors at many sites within the CNS, increases pain threshold, alters pain reception, inhibits ascending pain pathways</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170589\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 3 to 12 years: Intranasal: 5 to 10 minutes (Borland 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Analgesic: IM: 7 to 8 minutes; IV: Almost immediate (maximal analgesic and respiratory depressant effects may not be seen for several minutes); Transdermal patch (initial placement): 6 hours; Transmucosal: 5 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: IM: 1 to 2 hours; IV: 0.5 to 1 hour; Transdermal (removal of patch/no replacement): Related to blood level; some effects may last 72 to 96 hours due to extended half-life and absorption from the skin, fentanyl concentrations decrease by ~50% in 20 to 27 hours; Transmucosal: Related to blood level; respiratory depressant effect may last longer than analgesic effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal, patch: Initial application: Drug is released at a nearly constant rate from the transdermal matrix system into the skin, where it accumulates; this results in a depot of fentanyl in the outer layer of skin. Fentanyl is absorbed into systemic circulation from the depot. This results in a gradual increase in serum concentration over the first 12 to 24 hours, followed by fairly constant concentrations for the remainder of the dosing interval. Absorption is decreased in cachectic patients (compared to normal size patients). Exposure to external heat increases drug absorption from patch.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal, device: At the activation of each dose, an electrical current is activated for 10 minutes, which moves a dose of fentanyl from the drug-containing reservoir through the skin and into the systemic circulation. Fentanyl concentrations increase slowly with device activation and continue to increase for ~5 minutes after the completion of each 10 minute dose. Absorption of fentanyl from the device increases as a function of time and is independent of frequency of dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal, buccal tablet and buccal film: Rapid, ~50% from the buccal mucosa; remaining 50% swallowed with saliva and slowly absorbed from GI tract.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal, lozenge: Rapid, ~25% from the buccal mucosa; 75% swallowed with saliva and slowly absorbed from GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Highly lipophilic, redistributes into muscle and fat; <b>Note:</b> IV fentanyl exhibits a 3-compartment distribution model. Changes in blood pH may alter ionization of fentanyl and affect its distribution between plasma and CNS</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>dss</sub>: Children: 0.05 to 14 years of age (after long-term continuous infusion): ~15 L/kg (range: 5 to 30 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>dss</sub>: Adults: 4 to 6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 79% to 87%, primarily to alpha-1 acid glycoprotein; also binds to albumin and erythrocytes; <b>Note:</b> Free fraction increases with acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, primarily via CYP3A4 by N-dealkylation (to norfentanyl) and hydroxylation to other inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: <b>Note:</b> Comparative studies have found the buccal film to have a 40% greater systemic exposure (ie, AUC) than the transmucosal lozenge, and the buccal tablet to have a 30% to 50% greater exposure than the transmucosal lozenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal film: 71% (mucositis did not have a clinically significant effect on C<sub>max</sub> and AUC; however, bioavailability is expected to decrease if film is inappropriately chewed and swallowed)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal tablet: 65%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lozenge: ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual spray: 76%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet: 54%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 5 months to 4.5 years: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 6 months to 14 years (after long-term continuous infusion): ~21 hours (range: 11-36 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2 to 4 hours; when administered as a continuous infusion, the half-life prolongs with infusion duration due to the large volume of distribution (Sessler 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal device: Terminal: ~16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch: 20 to 27 hours (apparent half-life is influenced by continued fentanyl absorption from skin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal products: 3 to 14 hours (dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: 15 to 25 hours (based on a multiple-dose pharmacokinetic study when doses are administered in the same nostril and separated by a 1-, 2-, or 4-hour time lapse)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal film: ~14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal tablet: 100-200 mcg: 3 to 4 hours; 400 to 800 mcg: 11 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal film: 0.75 to 4 hours (median: 1 hour)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal tablet: 20 to 240 minutes (median: 47 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lozenge: 20 to 480 minutes (median: 20 to 40 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: Median: 15 to 21 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual spray: 10 to 120 minutes (median: 90 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet: 15 to 240 minutes (median: 30 to 60 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch: 20 to 72 hours; steady state serum concentrations are reached after two sequential 72-hour applications</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine 75% (primarily as metabolites, &lt;7% to 10% as unchanged drug); feces ~9%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Newborn infants: Clearance may be significantly correlated to gestational age and birth weight (Saarenmaa 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989383\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Subsys Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (1): $70.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (1): $93.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (1): $141.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (1): $188.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (1): $234.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1200 (600 X 2) mcg (2): $376.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1600 (800 X 2) mcg (2): $469.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lozenge</b> (Actiq Buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (1): $68.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (1): $87.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (1): $106.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (1): $126.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1200 mcg (1): $164.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1600 mcg (30): $6,076.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lozenge</b> (FentaNYL Citrate Buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (30): $564.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (30): $714.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (30): $875.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (30): $1,037.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1200 mcg (30): $1,348.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1600 mcg (30): $1,663.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Ionsys Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/ACT (1): $240.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-100 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/hr (5): $958.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-12 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mcg/hr (5): $214.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-25 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg/hr (5): $258.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-50 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/hr (5): $473.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-75 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg/hr (5): $722.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (FentaNYL Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mcg/hr (5): $101.51</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg/hr (5): $72.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mcg/hr (5): $326.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/hr (5): $131.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62.5 mcg/hr (5): $474.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg/hr (5): $201.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">87.5 mcg/hr (5): $646.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/hr (5): $267.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/2 mL (2 mL): $1.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg/5 mL (5 mL): $2.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500MCG/10ML (10 mL): $3.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg/20 mL (20 mL): $10.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 mcg/50 mL (50 mL): $21.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 mcg/50 mL (50 mL): $34.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/100 mL 0.9% (100 mL): $17.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25MG/250ML 0.9% (250 mL): $26.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/100 mL 0.9% (100 mL): $32.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1MG/250ML 0.9% (250 mL): $25.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5MG/250ML 0.9% (250 mL): $39.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5MG/250ML 0.9% (250 mL): $64.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250MCG/50ML 0.9% (50 mL): $20.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lazanda Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/ACT (1): $1,038.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/ACT (1): $1,450.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg/ACT (1): $1,656.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (FentaNYL Citrate (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/2 mL (2 mL): $2.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (FentaNYL Citrate (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/2 mL (2 mL): $4.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (FentaNYL Citrate-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15MCG/3ML 0.9% (3 mL): $5.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MCG/5ML 0.9% (5 mL): $11.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500MCG/50ML 0.9% (50 mL): $16.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Abstral Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (32): $1,678.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (32): $2,107.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg (32): $2,527.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (32): $3,040.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (32): $3,916.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (32): $4,790.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fentora Buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (1): $59.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (1): $74.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (28): $3,030.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (28): $3,933.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (28): $4,846.38</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170596\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abstral (BM, ES, GB, HR, IE, PH, QA, TR);</li>\n      <li>Acref (JP);</li>\n      <li>Actiq (AU, CH, DE, DK, ES, FI, FR, GB, IE, IL, KR, PT, SE);</li>\n      <li>Adolor (CZ);</li>\n      <li>Breakyl (CZ, GB, LV);</li>\n      <li>Denpax (AU);</li>\n      <li>Dolforin (BG, CZ, LV);</li>\n      <li>Durasic (BD);</li>\n      <li>Durogesic (AE, AU, BH, CN, CO, CY, EG, ES, ID, IN, JO, KW, LB, LK, MX, NZ, PH, PK, PY, QA, SA, SG, TH, VN);</li>\n      <li>Durogesic D Trans (HK, KR, PE, TW);</li>\n      <li>Durogesic D-Trans (BR);</li>\n      <li>Durotep MT (JP);</li>\n      <li>Dyurohezik (UA);</li>\n      <li>Effentora (EE, ES, GB, IE, MT);</li>\n      <li>Fantamax (SG);</li>\n      <li>Fencino (GB);</li>\n      <li>Fent (LK);</li>\n      <li>Fenta (IL);</li>\n      <li>Fentaderm Patch (KR);</li>\n      <li>Fentadermal (PH);</li>\n      <li>Fentadur Patch (KR);</li>\n      <li>Fentalis (GB, IE);</li>\n      <li>Fentamax Mat Patch (KR);</li>\n      <li>Fentanest (BR, IT, MX, PY, UY);</li>\n      <li>Fentanila (CL);</li>\n      <li>Fentanilo (CU, VE);</li>\n      <li>Fentanyl (CR, DO, GT, NI, PA, SV);</li>\n      <li>Fentanyl Citrate (EC);</li>\n      <li>Fentax (PY);</li>\n      <li>Fentora (HK);</li>\n      <li>Fentos Tape (JP);</li>\n      <li>Filtaten (MX);</li>\n      <li>Instanyl (AT, BE, CZ, DE, DK, EE, ES, FR, HR, IS, LT, LU, MT, NL, PL, SE, SI, SK);</li>\n      <li>Instanyl Nasal (GB, NO);</li>\n      <li>Ionsys (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PT, RU, SE, SK, TR);</li>\n      <li>Leptanal (SE);</li>\n      <li>Lunaldin (LV);</li>\n      <li>Matrifen (BE, DK, EE, GB);</li>\n      <li>Mezolar Matrix (GB);</li>\n      <li>Oncolis (BM);</li>\n      <li>One Duro (JP);</li>\n      <li>Opifen (BD);</li>\n      <li>Opiodur (GB);</li>\n      <li>Osmanil (GB);</li>\n      <li>PecFent (GB);</li>\n      <li>Pentyl (BD);</li>\n      <li>Recivit (GB);</li>\n      <li>Sublimaze (AR, AU, GB, IE, NZ, PH, ZA);</li>\n      <li>Tanyl (IL);</li>\n      <li>Trofentyl (IN, PH);</li>\n      <li>Vellofent (RO);</li>\n      <li>Verfen (LK);</li>\n      <li>Victanyl (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abstral (fentanyl) [prescribing information]. Solana Beach, CA: Sentynl Therapeutics Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abstral (fentanyl) [product monograph]. St-Laurent, Quebec, Canada: Paladin Labs Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 36, July 2002. Obstetric Analgesia and Anesthesia,&quot; <i>Obstet Gynecol</i>, 2002, 100(1):177-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/12100826/pubmed\" target=\"_blank\" id=\"12100826\">12100826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Actiq (fentanyl) [prescribing information]. Fraiser, PA: Cephalon Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey PL, Pace NL, Ashburn MA, et al, &ldquo;Frequent Hypoxemia and Apnea After Sedation With Midazolam and Fentanyl,&rdquo; <i>Anesthesiology</i>, 1990, 73(5):826-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/2122773/pubmed\" target=\"_blank\" id=\"2122773\">2122773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barash PG, Cullen BF, Stoelting RK, et al, eds, <i>Clinical Anesthesia</i>, 6th ed, Philadelphia, PA; Lippincott Williams &amp; Wilkins, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bedforth NM and Lockey DJ, &ldquo;Raynaud's Syndrome Following Intravenous Induction of Anaesthesia,&rdquo; <i>Anaesthesia</i>, 1995, 50(3):248-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/7717494/pubmed\" target=\"_blank\" id=\"7717494\">7717494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bennett MR and Adams AP, &ldquo;Postoperative Respiratory Complications of Opiates,&rdquo; <i>Clin Anaesthesiol</i>, 1983, 1:41-56.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borland M, Jacobs I, King B, et al, &quot;A Randomized Controlled Trial Comparing Intranasal Fentanyl to Intravenous Morphine for Managing Acute Pain in Children in the Emergency Department,&quot; <i>Ann Emerg Med</i>, 2007, 49(3):335-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/17067720/pubmed\" target=\"_blank\" id=\"17067720\">17067720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou R, Fanciullo GJ, Fine PG, et al, &quot;Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,&quot;<i> J Pain</i>, 2009, 10(2):113-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debono M, Chan S, Rolfe C, Jones TH. Tramadol-induced adrenal insufficiency. <i>Eur J Clin Pharmacol</i>. 2011;67(8):865-867.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/21243342/pubmed\" target=\"_blank\" id=\"21243342\">21243342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dionne RA, Yagiela JA, Moore PA, et al, &ldquo;Comparing Efficacy and Safety of Four Intravenous Sedation Regimens in Dental Outpatients,&rdquo; <i>Am Dent Assoc</i>, 2001, 132(6):740-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/11433853 /pubmed\" target=\"_blank\" id=\"11433853 \">11433853 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain&mdash;United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duragesic (fentanyl transdermal system) [prescribing information]. Titusville, NJ: Janssen; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duragesic (fentanyl transdermal system) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fentanyl citrate injection, USP (fentanyl) [product monograph]. Saint Laurent, Quebec, Canada: Hospira Healthcare Corporation; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fentora (fentanyl) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fentora (fentanyl) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fine PG, &ldquo;Fentanyl in the Treatment of Cancer Pain,&rdquo; <i>Semin Oncol</i>, 1997, 24(5 Suppl 16):16-20-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furuya H and Okumura F, &ldquo;Hemolysis After Administration of High Dose Fentanyl,&rdquo; <i>Anesth Analg</i>, 1986, 65(2):207-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/3942312/pubmed\" target=\"_blank\" id=\"3942312\">3942312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gomar C and Fernandez C, &ldquo;Epidural Analgesia-Anaesthesia in Obstetrics,&rdquo; <i>Eur J Anaesthesiol</i>, 2000, 17(9):542-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/11029122/pubmed\" target=\"_blank\" id=\"11029122\">11029122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heiskanen T, Matzke S, Haakana S, et al, &ldquo;Transdermal Fentanyl in Cachectic Cancer Patients,&rdquo; <i>Pain</i>, 2009, 144(1-2):218-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/19442446/pubmed\" target=\"_blank\" id=\"19442446\">19442446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ionsys (fentanyl transdermal system) [prescribing information]. Parsippany, NJ: The Medicines Company; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeal W and Benfield P, &ldquo;Transdermal Fentanyl. A Review of Its Pharmacological Properties and Therapeutic Efficacy in Pain Control,&rdquo; <i>Drugs</i>, 1997, 53(1):109-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/9010652/pubmed\" target=\"_blank\" id=\"9010652\">9010652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornick CA, Santiago-Palma J, Khojainova N, et al, &ldquo;A Safe and Effective Method for Converting Cancer Patients from Intravenous to Transdermal Fentanyl,&rdquo; <i>Cancer</i>, 2001, 92(12):3056-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/11753984/pubmed\" target=\"_blank\" id=\"11753984\">11753984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazanda (fentanyl citrate spray) [prescribing information]. Newark, CA: Depomed Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu LL and Gropper MA, &ldquo;Postoperative Analgesia and Sedation in the Adult Intensive Care Unit,&rdquo; <i>Drugs</i>, 2003, 63(8):755-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/12662124/pubmed\" target=\"_blank\" id=\"12662124\">12662124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandel L, Carunchio MJ. Rampant caries from oral transmucosal fentanyl citrate lozenge abuse. <i>J Am Dent Assoc.</i> 2011;142(4):406-409.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manion SC, Brennan TJ. Thoracic epidural analgesia and acute pain management. <i>Anesthesiology</i>. 2011;115(1):181-188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/21606825/pubmed\" target=\"_blank\" id=\"21606825\">21606825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, <i>Miller&rsquo;s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Momeni M, Crucitti M, and De Kock M, &ldquo;Patient Controlled Analgesia in the Management of Postoperative Pain,&rdquo; <i>Drugs</i>, 2006, 66(18):2321-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/17181375/pubmed\" target=\"_blank\" id=\"17181375\">17181375</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pang WW, Huang S, Chung YT, et al, &ldquo;Comparison of Intravenous Retention of Fentanyl and Lidocaine on Local Analgesia in Propofol Injection Pain,&rdquo; <i>Acta Anaesthesiol Sin</i>, 1997, 35(4):217-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/9553237/pubmed\" target=\"_blank\" id=\"9553237\">9553237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patanwala AE, Keim SM, and Erstad BL, Intravenous opioids for severe acute pain in the emergency department, <i>Ann Pharmacother</i>, 2010, 44:1800-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/20978218/pubmed\" target=\"_blank\" id=\"20978218\">20978218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peng PW and Sandler AN, &ldquo;A Review of the Use of Fentanyl Analgesia in the Management of Acute Pain in Adults,&rdquo; <i>Anesthesiology</i>, 1999, 90(2):576-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/9952166/pubmed\" target=\"_blank\" id=\"9952166\">9952166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saarenmaa E, Neuvonen PJ, and Fellman V, &ldquo;Gestational Age and Birth Weight Effects on Plasma Clearance of Fentanyl in Newborn Infants,&rdquo; <i>J Pediatr</i>, 2000, 136(6):767-770.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/10839874/pubmed\" target=\"_blank\" id=\"10839874\">10839874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scholz J, Steinfath M, and Schulz M, &ldquo;Clinical Pharmacokinetics of Alfentanil, Fentanyl, and Sufentanil. An Update,&rdquo; <i>Clin Pharmacokinet</i>, 1996, 31(4):275-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/8896944/pubmed\" target=\"_blank\" id=\"8896944\">8896944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sessler CN and Varney K, &ldquo;Patient-Focused Sedation and Analgesia in the ICU,&rdquo; <i>Chest</i>, 2008, 133(2):552-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/18252923/pubmed\" target=\"_blank\" id=\"18252923\">18252923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spigset O and Hagg S, &ldquo;Analgesics and Breast-feeding: Safety Considerations,&rdquo; <i>Paediatr Drugs</i>, 2000, 2(3):223-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-drug-information/abstract-text/10937472/pubmed\" target=\"_blank\" id=\"10937472\">10937472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Sublimaze</i> [package insert]. Lake Forest, IL; Akorn: January 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Subsys (fentanyl spray) [prescribing information]. Chandler, AZ: Insys Therapeutics; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL The sugar-loaded fentanyl lollipop (Actiq) and the risk of tooth decay. <i>Gen Den.</i> 2011;59(3):168-170.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8441 Version 248.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50847583\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708780\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F170610\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F170611\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F170659\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F170615\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F170639\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F170616\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14936198\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F170617\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F170583\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F170567\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10461326\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28106456\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F170661\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F50183666\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874432\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F170587\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472636\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472637\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F170586\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F170670\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F170574\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F170590\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F170571\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F170653\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F170576\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F170606\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F170578\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F170593\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F170594\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F170595\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F170580\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F170570\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F170589\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989383\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F170596\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8441|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fentanyl-patient-drug-information\" class=\"drug drug_patient\">Fentanyl: Patient drug information</a></li><li><a href=\"topic.htm?path=fentanyl-pediatric-drug-information\" class=\"drug drug_pediatric\">Fentanyl: Pediatric drug information</a></li></ul></div></div>","javascript":null}